Development of Clarstatin, a Novel Drug Lead for the Therapy of Autoimmune Uveitis.
backbone cyclization
calreticulin
experimental autoimmune uveoretinitis
inflammatory autoimmune diseases
peptidomimetic
peptomer
thiourea-bridged
uveitis
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
27 May 2024
27 May 2024
Historique:
received:
09
05
2024
revised:
21
05
2024
accepted:
23
05
2024
medline:
27
6
2024
pubmed:
27
6
2024
entrez:
27
6
2024
Statut:
epublish
Résumé
We describe the design, synthesis, and activity of a potent thiourea-bridged backbone cyclic peptidomimetic known as Clarstatin, comprising a 5-amino acid sequence (Q/D)
Identifiants
pubmed: 38931845
pii: pharmaceutics16060723
doi: 10.3390/pharmaceutics16060723
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : a Kamin grant from the Israel Innovation Authority
ID : 67970